相关实验视频

Updated: May 10, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

16.8K

纳米粒子癌症药物的开发者担心申请破产

Heidi Ledford

    Nature
    |May 20, 2016
    PubMed
    概括

    No abstract available in PubMed .

    更多相关视频

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
    07:59

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

    Published on: March 4, 2017

    9.5K
    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
    09:34

    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

    Published on: February 9, 2019

    9.5K

    相关实验视频

    Last Updated: May 10, 2026

    Manufacture and Drug Delivery Applications of Silk Nanoparticles
    09:03

    Manufacture and Drug Delivery Applications of Silk Nanoparticles

    Published on: October 8, 2016

    16.8K
    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
    07:59

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

    Published on: March 4, 2017

    9.5K
    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
    09:34

    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

    Published on: February 9, 2019

    9.5K

    相关概念视频

    Preclinical Development: Overview01:28

    Preclinical Development: Overview

    Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
    JoVE
    关于 JoVE
    概览领导团队博客JoVE 帮助中心
    作者
    出版流程编辑委员会范围与政策同行评审常见问题投稿
    图书馆员
    用户评价订阅访问资源图书馆顾问委员会常见问题
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
    使用条款与条件
    隐私政策
    政策
    Jove
    Visualize
    联系我们